Clinical Trial: NCT05800366
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Jennifer Crombie, MD |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-03-05 |
Study Overview
Brief Summary
The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma.
The names of the treatment interventions involved in this study are:
- Glofitamab (T-cell bispecific antibody)
- Polatuzumab (antibody-drug conjugate)
- R-CHP (a chemotherapy regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, and Prednisone)
Official Title
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Conditions
Lymphoma, Lymphoma, Large B-Cell, Diffuse
Intervention / Treatment
- Drug: Glofitamab
- Drug: Polatuzumab
- Drug: Rituximab
- Drug: Doxorubicin Hydrochloride
- Drug: Cyclophosphamide
- Drug: Prednisone
Other Study ID Numbers
- 22-606
Start Date (Actual)
2023-04-06
Primary Completion Date (Estimated)
2026-09-15
Study Completion Date (Estimated)
2029-09-15
Enrollment (Estimated)
41
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Jennifer Crombie, MD |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-03-05 |
Study Overview
Brief Summary
The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma.
The names of the treatment interventions involved in this study are:
- Glofitamab (T-cell bispecific antibody)
- Polatuzumab (antibody-drug conjugate)
- R-CHP (a chemotherapy regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, and Prednisone)
Official Title
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Conditions
Lymphoma, Lymphoma, Large B-Cell, Diffuse
Intervention / Treatment
- Drug: Glofitamab
- Drug: Polatuzumab
- Drug: Rituximab
- Drug: Doxorubicin Hydrochloride
- Drug: Cyclophosphamide
- Drug: Prednisone
Other Study ID Numbers
- 22-606
Start Date (Actual)
2023-04-06
Primary Completion Date (Estimated)
2026-09-15
Study Completion Date (Estimated)
2029-09-15
Enrollment (Estimated)
41
Study Type
Interventional
Phase
Phase 2